Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Novartis AG — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $80.96, while Novartis AG trades at $154.71 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals.
| IEMG | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $168.62 |
52-Week Low | $61.76 | $119.31 |
Market Cap | — | $295.37B |
Enterprise Value | — | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $80.97, up 1.77% with a bullish technical signal from moving averages. The ETF offers emerging markets exposure with a 0.09% expense ratio and significant technology weighting. Recent performance shows strong returns but elevated volatility compared to developed market alternatives.
The outlook remains positive given attractive valuations and growth potential in emerging markets, though concentration in tech/AI stocks and geopolitical risks warrant monitoring. Current technical indicators show potential resistance near $81 with support at $79-80 levels.
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
